止痒洗剂联合妇炎消生物敷料栓治疗妊娠合并外阴阴道假丝酵母菌病临床研究

目的:观察止痒洗剂联合妇炎消生物敷料栓治疗妊娠合并外阴阴道假丝酵母菌病(Vulvovaginal candidiasis,VVC)的临床疗效。方法:选取2012年8月—2015年8月本院收治的70例妊娠合并VVC患者,随机分为研究组和对照组,每组各35例。对照组给予妇炎消生物敷料栓治疗,研究组在对照组的基础上联合止痒洗剂。观察两组患者临床症状体征改善情况、临床疗效及复发情况。结果:研究组外阴瘙痒、外阴红肿、阴道充血改善率分别为97.1%、85.7%、82.9%,对照组分别为88.6%、71.4%、74.3%,两组患者临床症状体征改善情况比较,差异均有统计学意义(P0.05)。研究组有效率为88.6%,对照组有效率为60.0%,两组患者临床疗效比较,差异具有统计学意义(P0.05)。研究组复发率为2.9%,对照组复发率为14.3%,两组患者复发率比较,差异具有统计学意义(P0.05)。结论:止痒洗剂联合妇炎消生物敷料栓能够有效改善妊娠合并VVC患者的临床症状,降低复发率。     

康妇消炎栓对子宫肌瘤术后血清C反应蛋白、白细胞计数及肠胃功能恢复的影响

目的:探究康妇消炎栓对子宫肌瘤术后患者血清C反应蛋白(CRP)、白细胞计数(WBC)水平及肠胃功能恢复的影响。方法:选取2017年1月至2017年11月马鞍山市中心医院收治的子宫肌瘤患者80例作为研究对象,按照随机数字表法分为对照组和观察组,每组40例。对照组给予术后常规预防性抗炎,观察组在此基础上给予康妇消炎栓塞肛治疗,比较2组患者治疗效果、麻醉时间、手术时间、CRP、WBC及肠胃功能恢复情况,如术后首次排气时间、术后首次排便时间等。结果:治疗后,2组患者CRP、WBC水平较治疗前降低,而且观察组CRP、WBC水平较对照组低(P0.05)。2组手术时间及麻醉时间比较,差异无统计学意义(P0.05),观察组术后首次排气时间、术后首次排便时间与对照组比较差异有统计学意义(P=0.002、0.0080.05)。观察组治疗有效率95.00%,对照组为77.50%,差异有统计学意义(P0.05)。结论:康妇消炎栓应用于子宫肌瘤术后患者,能够降低术后炎症反应,促进术后肠胃功能恢复,值得推广。     

纠正菌群失调在治疗孕妇复发性念珠菌性阴道炎的价值

目的:观察延华胶囊用于孕妇复发性念珠茼性阴道炎的疗效。方法:随机选取120例复发性念珠菌性阴道炎的妊娠妇女,采用达克宁栓治疗作为对照组(n=60),每天一次400mg阴道用药,连续14d,采用延华胶囊和达克宁栓联合治疗为治疗组(n=60),延华胶囊0.5g,1次/d阴道上药,连用7d.而后用达克宁栓400mg,1次/d阴道上药,连用7d,比较两组疗效。结果:治疗组治愈率为81.7％,对照组治愈率65％,两组治愈率比较差异有显著性,两组有效率分别为95％和83.3％,差异有显著性(P<0.05)。结论:延华胶囊和达克宁栓联合治疗孕妇复发性念珠菌性阴道炎有显著疗效。     

保妇康栓治疗宫颈炎合并HPV感染的临床分析

目的 观察保妇康栓治疗宫颈炎合并人乳头瘤病毒(HPV)感染的临床效果.方法 对我院2012年1月至2014年2月门诊治疗的30例宫颈炎合并人乳头瘤病毒(HPV)感染的患者展开临床治疗的研究,根据阴道用药方式的不同将其分为治疗组和对照组,治疗组行保妇康栓阴道给药治疗,对照组行干扰素栓阴道给药治疗;分析两组患者的临床治疗效果.结果 治疗组患者治疗总有效率达93.3％优于对照组的73.3％;复发率为6.7％低于对照组的33.3％,组间比较x2=14.10、21.01;治疗后两组患者间的HPV检测RLU/CO值比较t=2.08;差异具有统计学意义(P＜0.05).结论 保妇康栓对宫颈炎合并HPV感染的治疗具有明显的临床效果,有效降低复发率.     

宫颈高危型人乳头状瘤病毒感染中药配合保妇康治疗效果的临床研究

目的探讨宫颈高危型人乳头状瘤病毒(HPV)感染中药配合保妇康治疗临床效果,以寻找最佳的治疗方法,提高临床治疗水平。方法选取2011年12月-2013年12月130例宫颈高危型HPV感染患者为研究对象,将其分成对照组及观察组,每组各65例,对照组予保妇康治疗,观察组在对照组基础上加用中药治疗,观察治疗后两组临床效果差异性,数据采用SPSS16.0软件进行统计分析。结果治疗总有效率及HPV转阴率,对照组分别为80.00%及63.08%,观察组分别为92.31%及90.77%,两组比较差异有统计学意义(P<0.05);治疗后两组患者临床症状体征积分、中医证候积分比较,差异均有统计学意义(P<0.05);两组患者治疗后均无不良反应发生。结论中药配合保妇康治疗宫颈高危型HPV感染临床效果满意,安全性高。     

保妇康凝胶联合诺氟沙星治疗宫颈糜烂50例疗效观察

目的：探讨保妇康凝胶联合诺氟沙星治疗宫颈糜烂的临床效果。方法将100例宫颈糜烂患者根据随机数字表法分为观察组和对照组各50例。观察组给予保妇康凝胶和诺氟沙星联合治疗，对照组单独给予治糜灵栓治疗，比较两组患者临床症状的变化，并对临床疗效进行评价。结果观察组治愈率为86.00%，明显高于对照组的74.00%，临床症状评分改善较对照组明显，且其临床症状消失的时间短于对照组，差异均有统计学意义(P<0.05)。结论保妇康凝胶与诺氟沙星合用比治糜灵栓治疗宫颈糜烂效果更佳，且治愈时间上明显较优，值得临床上推广应用。     

Recombinant streptokinase vs hydrocortisone suppositories in acute hemorrhoids: A randomized controlled trial

AIM: To compare the efficacy and safety of recombinant streptokinase(rSK) vs hydrocortisone acetate-based suppositories in acute hemorrhoidal disease.METHODS: A multicenter(11 sites), randomized(1:1:1), open, controlled trial with parallel groups was performed. All participating patients gave their written,informed consent. After inclusion, patients with acute symptoms of hemorrhoids were centrally randomized to receive, as outpatients, by the rectal route, suppositories of rSK 200000 IU of one unit every 8 h(first 3 units)and afterwards every 12 h until 8 administrations were completed(schedule A), one unit every 8 h until 6 units were completed(schedule B), or 25 mg hydrocortisone acetate once every 8 h up to a maximum of 24 administrations. Evaluations were performed at 3, 5,and 10 d post-inclusion. The main end-point was the 5thday response(disappearance of pain and bleeding, and≥ 70% reduction of the lesion size). Time to response and need for thrombectomy were secondary efficacy variables. Adverse events were also evaluated.RESULTS: Groups were homogeneous with regards to demographic and baseline characteristics. Fifth day complete response rates were 156/170(91.8%; 95%CI:87.3-96.2), 155/170(91.2%; 95%CI: 86.6%-95.7%),and 46/170(27.1%; 95%CI: 20.1%-34.0%) with rSK(schedule A and B) and hydrocortisone acetate suppositories, respectively. These 64.6% and 63.9%differences(95%CI: 56.7%-72.2% and 55.7%-72.0%)were highly significant(P 0.001). This advantage was detected since the early 3rd day evaluation(68.8% and64.1% vs 7.1% for the rSK and active control groups,respectively; P 0.001) and was maintained even at the late 10 th day assessment(97.1% and 93.5% vs67.1% for rSK and hydrocortisone acetate, respectively;P 0.001). Time to response was 3 d(95%CI: 2.9-3.1)for both rSK groups and 10 d(95%CI: 9.3-10.7) in the hydrocortisone acetate group. This difference was highly significant(P 0.001). All subgroup stratified analyses(with or without thrombosis and hemorrhoid classification) showed a statistically significant advantage for the rSK groups. Thrombectomy was necessary in4/251 and 14/133 patients with baseline thrombosis in the rSK and hydrocortisone acetate groups, respectively(P 0.001). There were no adverse events attributable to the experimental treatment.CONCLUSION: rSK suppositories showed a significant advantage over a widely-used over-the-counter hydrocortisone acetate preparation for the treatment of acute hemorrhoidal illness, as well as having an adequate safety profile.     

康复新液对HPV阳性宫颈糜烂患者转阴的临床效果研究

目的：观察康复新液对HPV阳性患者转阴的治疗作用。方法对门诊治疗的宫颈糜烂患者,给予HPV筛查,对筛查阳性的162例患者,随机分为研究组和对照组,研究组给予康复新液阴道用药治疗12个月,对照组给予保妇康栓阴道用药12个月,比较治疗效果和HPV转阴情况。结果研究组治疗效果明显好于对照组,治疗12个月时,痊愈61例(75．31%),好转11例(13．58%),无效9例(11．11%),有效率88．89%;对照组治疗12个月时,痊愈36例(44．44%),好转12例(14．81%),无效33例(40．74%),有效率59．26%。研究组转阴36例(44．44%),显著改善32例(39．51%),改善5例(6．17%),无改善8例(9．88%),升高0例(0．00%),改善率90．12%;对照组转阴21例(25．93%),显著改善22例(27．16%),改善6例(7．41%),无改善31例(38．27%),升高1例(1．23%),改善率60．49%。结论康复新液用于治疗HPV阳性宫颈糜烂患者,不仅有利于病情更好恢复,而且对HPV转阴有临床价值,因而对宫颈糜烂发生癌变有预防作用。     

双歧杆菌三联活菌胶囊联合美沙拉嗪栓剂治疗UC的临床观察

目的：探讨双歧杆菌三联活菌胶囊联合美沙拉嗪栓剂治疗溃疡性结肠炎（UC）的临床疗效及安全性。方法将收治的60例UC患者按随机数字表分为观察组和对照组,每组30例。2组均予美沙拉嗪栓剂治疗,1 g/次,2次/d,塞肛,在此基础上,观察组加用双歧杆菌三联活菌胶囊,0.42g/次,3次/d,饭后半小时温水服用。2组疗程均为4周。观察治疗前后的临床疗效、改良Mayo评分及不良反应发生率,进行对比分析。结果观察组的总有效率为93.33%,与对照组比较,差异有统计学意义（P＜0.05）。2组治疗后的改良Mayo评分分别为（1.19±1.72）分、（3.21±1.36）分,组间比较,观察组的改善优于对照组（P＜0.05）,而2组不良反应发生率分别为6.67%。13.33%,组间比较无统计学意义。结论培菲康联合美沙拉嗪栓剂治疗溃疡性结肠炎疗效显著。